NextCure, Inc. (NXTC) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.83
↑+53% vs avg
5yr avg: 0.54
30Y Low0.2·High2.8
ROE
↓
-111.2%
↑-98% vs avg
5yr avg: -56.2%
30Y Low-111%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NXTC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NextCure, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $27M | $40M | $22M | $32M | $39M | $166M | $300M | $884M | — | — |
| Enterprise Value | $5M | $19M | $-221930 | $25M | $20M | $153M | $271M | $855M | — | — |
| P/E Ratio → | -0.52 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 13.41 | 139.30 | — | — |
| P/B Ratio | 0.83 | 1.15 | 0.33 | 0.28 | 0.23 | 0.71 | 1.02 | 2.75 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NXTC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 12.10 | 134.74 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
NXTC Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -111.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | -108.0% | -439.1% | — | — |
| Operating Margin | — | — | — | — | — | — | -184.2% | -590.5% | — | — |
| Net Profit Margin | — | — | — | — | — | — | -163.6% | -531.5% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -111.2% | -111.2% | -61.9% | -44.5% | -37.3% | -26.3% | -11.9% | -24.6% | — | — |
| ROA | -85.2% | -85.2% | -53.3% | -40.2% | -35.0% | -25.3% | -11.0% | -13.4% | -27.3% | -79.5% |
| ROIC | -152.1% | -152.1% | -59.1% | -39.6% | -30.9% | -21.9% | -11.1% | -50.7% | — | — |
| ROCE | -103.9% | -103.9% | -62.1% | -45.7% | -37.0% | -26.6% | -12.9% | -15.7% | -30.2% | -95.1% |
NXTC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $26M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.09 | 0.06 | 0.04 | — | 0.01 | 0.02 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.62 | -0.33 | -0.06 | -0.12 | -0.05 | -0.10 | -0.09 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | -27.30 | — |
| Interest Coverage | — | — | — | — | — | -919.03 | -225.27 | -179.34 | — | — |
Net cash position: cash ($26M) exceeds total debt ($4M)
NXTC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
NextCure, Inc.'s current ratio of 4.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 16.38x to 4.14x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.14 | 4.14 | 7.50 | 16.38 | 17.97 | 34.48 | 27.89 | 22.60 | 13.19 | 3.02 |
| Quick Ratio | 4.14 | 4.14 | 7.50 | 16.38 | 18.04 | 34.48 | 27.89 | 22.60 | 13.19 | 3.02 |
| Cash Ratio | 3.96 | 3.96 | 7.17 | 15.73 | 17.52 | 33.23 | 27.45 | 22.24 | 13.13 | 2.70 |
| Asset Turnover | — | — | — | — | — | — | 0.07 | 0.02 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
NXTC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NextCure, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $3M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | $2M |
Peer Comparison
Compare NXTC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NXTCYou | $27M | -0.5 | — | — | — | — | -111.2% | -152.1% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 INCY | $20B | 15.3 | 11.5 | 14.4 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 EXEL | $12B | 16.6 | 12.7 | 13.9 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 ALKS | $6B | 24.8 | 17.3 | 12.3 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See NXTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NXTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NXTC vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonNXTC — Frequently Asked Questions
Quick answers to the most common questions about buying NXTC stock.
What is NextCure, Inc.'s P/E ratio?
NextCure, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
What is NextCure, Inc.'s ROE?
NextCure, Inc.'s return on equity (ROE) is -111.2%. The historical average is -45.4%.
Is NXTC stock overvalued?
Based on historical data, NextCure, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.